# Ipamorelin FAQ: WADA, Detection, Effects, and Stack Questions Answered > Ipamorelin FAQ: is it banned by WADA, can a drug test detect it, what it does, the risks, the CJC-1295 stack — direct, cited answers. No dosing recommendations. The questions people actually type — WADA status, detection, effects, the CJC-1295 stack — answered directly and cited where there's a number. ## Is ipamorelin banned by WADA? Yes. Ipamorelin is on the WADA Prohibited List under category S2 (peptide hormones, growth factors, related substances and mimetics), banned at all times — in and out of competition. It's a growth hormone secretagogue, and analytical methods determine GHRP metabolites in human urine, so the ban is enforceable, not symbolic [7]. ## Can ipamorelin be detected in a drug test? Yes, by accredited anti-doping labs. Detection targets metabolites in urine rather than the intact peptide, so its short ~2-hour plasma half-life doesn't make it undetectable [2][7]. Published methods screen for the GHRP class, and labs have even characterized designer analogues like Gly-Ipamorelin in seized products [9]. Detection is method-backed and real. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the ghrelin receptor (GHS-R1a). It triggers a pulse of growth hormone from the pituitary, and its defining feature is selectivity: it does so without meaningfully raising cortisol or prolactin, unlike older GHRPs [1]. It is a research peptide, not an approved drug. ## What does ipamorelin do for you? In studies, ipamorelin releases a pulse of growth hormone by activating the ghrelin receptor, potently in rats and pigs without spiking cortisol [1]. In rats it increased bone growth [4]. In humans, the picture is thin and its one efficacy trial failed [3]. People report better sleep and recovery anecdotally, but those aren't trial findings. It's not approved to do anything for anyone. ## What is ipamorelin peptide? "Ipamorelin peptide" is just ipamorelin — a five-amino-acid synthetic peptide (C38H49N9O5, ~711.9 Da, CAS 170851-70-4) that selectively activates GHS-R1a to release growth hormone [1]. It was developed as the first selective growth hormone secretagogue. It is a research chemical, not an endogenous human peptide and not a drug product. ## What are the risks of ipamorelin? The honest answer: largely uncharacterized in humans. The only Phase 2 RCT (n=114, 7 days IV) showed no ipamorelin-specific safety signal in that short window but also failed on efficacy [3]. Class-level concerns include a cardiotoxicity signal from a related ghrelin agonist in rats [6], unpredictable glucose effects [10], and the theoretical IGF-1/cancer concern [1]. Long-term human safety data simply don't exist. ## Does ipamorelin reduce belly fat? There's no human trial showing ipamorelin reduces belly fat. The relevant in-vivo data is a 2024 ferret study where ipamorelin (1-3 mg/kg IP) blunted chemotherapy-induced weight loss ~24% — that's preventing loss, not burning fat [5]. Community reports of gradual leaner composition are anecdotal and confounded by diet and training. The fat-loss marketing outruns the evidence. ## What are the downsides of ipamorelin? Its single human efficacy trial failed [3], it's never been approved, it's banned in sport [7], and its long-term safety is unknown. Reported downsides include facial flushing, increased appetite, water retention, tingling, and injection-site irritation — all anecdotal. Class-level signals include a rat cardiotoxicity finding for a related agonist [6] and unpredictable glucose effects [10]. The evidence base is thin and partly negative. ## Why is ipamorelin being discontinued? Ipamorelin's clinical development effectively stopped because its only Phase 2 trial — for postoperative ileus — missed its primary endpoint (25.3 h vs 32.6 h, p=0.15), so no Phase 3 followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from the 503A Category 2 compounding list, tightening pharmacy access. It was never a discontinued *approved* drug — it was never approved in the first place. ## What does CJC-1295 and ipamorelin do? They're a two-peptide combination meant to stimulate growth hormone through complementary pathways: CJC-1295 via the GHRH receptor, ipamorelin via the ghrelin receptor [1]. The theory is an amplified GH pulse. But the combination has never been tested together in a controlled human trial, so its real-world effects are extrapolated from each agent alone, not demonstrated [3]. ## Does ipamorelin increase IGF-1? It can, indirectly and context-dependently. Growth hormone drives hepatic IGF-1 production, so sustained GH-axis stimulation can raise IGF-1 — but short rodent ipamorelin studies showed dose-dependent bone growth with *no* measurable change in total IGF-1 [4]. So a guaranteed IGF-1 rise isn't a given; it depends on protocol, duration, and species. The link is real but not automatic. ## How does CJC-1295 ipamorelin work? Each peptide hits a different pituitary receptor. CJC-1295 is a GHRH analog acting on the GHRH receptor; ipamorelin is a selective GHS-R1a (ghrelin-receptor) agonist [1]. Because the two pathways are separate and complementary, co-stimulation is expected to produce a larger growth-hormone pulse than either alone — a mechanistic rationale, not a combination proven in human trials [3]. ## How much CJC-1295 ipamorelin should I take? There's no established or studied human dose for the combination, so this isn't a question with a legitimate answer. The combination has never been tested in a controlled human trial [3], and any figure circulating online is community lore with no peer-reviewed basis. This site reports doses studied in research only and gives no human protocols or recommendations. ## Does CJC-1295 ipamorelin work? For raising growth hormone, each component does so in its own studies, so a GH pulse is plausible. For outcomes like fat loss or muscle gain, no controlled human trial has tested the combination, and ipamorelin's own efficacy trial failed [3][11]. "Works" splits by claim: GH release is mechanistically supported; measurable real-world results are unproven for the stack. ## How to reconstitute CJC-1295 ipamorelin 5mg? This site doesn't provide a reconstitution or preparation procedure for any combination product — that crosses from describing research into instructing use. In general research-handling terms, ipamorelin ships as a lyophilized (freeze-dried) powder reconstituted with bacteriostatic water and kept refrigerated, as it degrades with heat and freeze-thaw [2]. Those are supply-literature observations, not a clinical method, volume, or dose. ## How long does ipamorelin stay in your system? Two answers. Clearance: terminal half-life ~2 hours in humans, so the peptide leaves blood quickly [2]. Detection: separate and longer — anti-doping labs target urinary metabolites, so a short half-life doesn't equal undetectable [7]. A precise day-count detection window for ipamorelin specifically isn't a tidy published figure; it depends on dose, route, and assay. See the half-life page for the full breakdown. ## Does ipamorelin make you hungry? Often, yes — it's built into the mechanism. Ipamorelin activates the ghrelin receptor (GHS-R1a), the same one the hunger hormone uses, so an appetite uptick after injecting is among the more commonly reported effects [1]. Community accounts call it milder than GHRP-6 but still real. This is anecdotal and mechanism-consistent, not a dosed clinical finding. ## Will I gain weight on ipamorelin? No human trial answers this directly. The 2024 ferret study showed ipamorelin reduced *loss* of weight during chemotherapy, not weight gain in healthy subjects [5]. Anecdotally, appetite increases and mild water retention are reported, which can nudge the scale short-term [3]. Any leaner-composition reports are confounded by diet and training. There's no controlled human bodyweight outcome to point to. ## Does ipamorelin increase appetite? Yes, plausibly — it's a ghrelin-receptor agonist, and ghrelin is the body's hunger signal, so appetite stimulation is intrinsic to the mechanism [1]. A 2026 sports-medicine review classifies ipamorelin as an investigational GH-axis secretagogue with this class-level profile [11]. Community reports describe an appetite bump after injecting, milder than GHRP-6. It's mechanism-consistent and anecdotal, not a dosed trial endpoint. ## What does ipamorelin peptide do? It selectively activates the ghrelin receptor (GHS-R1a) to release a pulse of growth hormone from the pituitary, without meaningfully raising cortisol or prolactin — its signature selectivity [1]. In rats it increased bone growth [4]; in humans the data is thin and its one efficacy trial failed [3]. It's a research peptide with no approved use. ## How long does it take for ipamorelin to work? Pharmacologically, fast: the GH pulse it triggers peaks around 40 minutes after dosing in human PK studies [2]. That's the acute hormonal effect, not a clinical outcome. Any subjective effects people report — sleep, recovery — are anecdotal and described as appearing over one to two weeks, with no controlled human timeline to confirm them. The measurable action is a single short GH pulse. ## Does ipamorelin cause water retention? Anecdotally, sometimes — mild puffiness in fingers, ankles, or face is occasionally reported, usually early and described as milder than older GHRP compounds. Mechanistically it's plausible because growth hormone influences sodium and fluid balance [3]. But there's no controlled human study quantifying water retention from ipamorelin specifically, so this stays a reported, mechanism-consistent effect rather than a measured finding. --- A receipts-first desk on ipamorelin — the WADA S2 ban, the urinary-detection paper trail, and the lone failed human trial each logged to source and kept apart from the sales-copy version; no clinic behind the desk and nothing here dosed, compounded, prescribed, or sold.